Tissue Regenix Group secures a multi-year distribution agreement

In a statement, Tissue Regenix said: “The initial agreement is for three years, subject to annual purchase minimums, and Joint Operations will add OrthoPure XT to its portfolio of products.

"Joint Operations already distributes orthopaedic equipment to the National Health Service and the private sector within the UK.”

Richard Forster, Managing Director of Joint Operations Ltd, commented,: "We are delighted to be working with Tissue Regenix to represent OrthoPure XT in the UK.

"As a company, we spend a great deal of time in ligament reconstructive surgery, and it is tremendously exciting to have a unique xenograft option to offer UK surgeons.

Mr Forster added: "In particular, we have been impressed by the quality of clinical outcomes being achieved through the Tissue Regenix clinical studies, and we look forward to these results being replicated nationwide over the coming years."

Daniel Lee, chief executive officer of Tissue Regenix, said: "We are excited to partner with Joint Operations, who are experts in the distribution of orthopaedic equipment within the UK where an estimated 30,000 ACL surgeries take place each year.

He added: “This strategic partnership will continue our reach into the UK, ensuring these markets have access to our pioneering medical technology, which will help to transform patient care."

Tissue Regenix’s technology removes DNA and other cellular material from animal and human soft tissue, leaving a tissue scaffold that can be used to repair diseased or damaged body structures